We have discovered a pagination error in several 2024 issues. The corrected citation details of all affected articles are listed below.
VOLUME 5, ISSUE 5
Shah M, Blest F, Blackmur J, Laird A, Dawson S, Aning J. Malignant upper urinary tract obstruction in cancer patients: a systematic review. BJUI Compass. 2024; 5(5): 519–530. 10.1002/bco2.340
Tesfai A, Norori N, Harding TA, Wong YH, Hobbs MD. Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: a rapid review. BJUI Compass. 2024; 5(5): 531–546. 10.1002/bco2.326
Loyala JV, Ang A, Down B, Howles SA. Urology never events in the United Kingdom: a retrospective 10‐year review. BJUI Compass. 2024; 5(5): 547–551. 10.1002/bco2.331
Eckrich J, Ellinger J, Cox A, Stein J, Ritter M, Blaikie A, Kuhn S, Buhr CR Urology consultants versus large language models: potentials and hazards for medical advice in urology. BJUI Compass. 2024; 5(5): 552–558. 10.1002/bco2.359
Kanthabalan A, Emmanuel A, Alexander C, Bhatt N, Chan V, Kalejaiye O, Narahari K, Kasivisvanathan V, Shabbir M An international survey of contemporary practices towards fertility assessment and preservation in patients undergoing radical inguinal orchidectomy for testicular cancer. BJUI Compass. 2024; 5(5): 559–567. 10.1002/bco2.356
Perrouin‐Verbe M‐A, Ochoa D‐C, Skews R, Acharya M, Prouza A, Hashim H. Quality of life outcomes after transobturator tape full removal surgeries: a monocentric experience. BJUI Compass. 2024; 5(5): 568–578. 10.1002/bco2.317
Cooper DM, Lines R, Shergill I. Cost‐effectiveness of resonance® metallic ureteral stent compared with standard polyurethane ureteral stents in malignant ureteric obstruction: a cost‐utility analysis. BJUI Compass. 2024; 5(5): 579–589. 10.1002/bco2.332
Almås B, Reisæter LAR, Markhus CE, Hjelle KM, Børretzen A, Beisland C. A preoperative magnetic resonance imaging can aid in staging and treatment choice for upper tract urothelial carcinoma. BJUI Compass. 2024; 5(5): 590–596. 10.1002/bco2.337
Yamashita R, Nakamura M, Notsu A, Asakura K, Usui K, Sakura Y, et al. Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy. BJUI Compass. 2024; 5(5): 597–603. 10.1002/bco2.336
Khalil M, Fishman A, Komorowski A, Franco I, Grasso M III. Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: paradigm shift emphasizing organ preservation. BJUI Compass. 2024; 5(5): 604–610. 10.1002/bco2.335
Guo L, Cid A, Cucci J, Kunkel B, Defeis L, Matthews M. Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker. BJUI Compass. 2024; 5(5): 611–615. 10.1002/bco2.338
Nilsson R, Næss‐Andresen T, Myklebust TÅ, Bernklev T, Kersten H, Haug ES. The association between pre‐diagnostic levels of psychological distress and adverse effects after radical prostatectomy. BJUI Compass. 2024; 5(5): 616–625. 10.1002/bco2.334
VOLUME 5, ISSUE 6
Sii S, Bolton J, Tempo J, Bolton D. Contemporary status of diagnostic endoluminal ultrasound and optical coherence tomography in the ureter. BJUI Compass. 2024; 5(6): 628–637. 10.1002/bco2.352
Lahoud J, Patel MI, Naher S, Mercieca‐Bebber R. A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion. BJUI Compass. 2024; 5(6): 638–654. 10.1002/bco2.339
Schiellerup NS, Kobberø H, Andersen K, Poulsen CA, Poulsen MH. Evaluation of Botox treatment in patients with chronic scrotal pain: protocol for a randomized double‐blinded control trial. BJUI Compass. 2024; 5(6): 655–661. 10.1002/bco2.349
Rowe SP, Krueger S, Gorin MA, Fishman EK. Cinematic rendering of 18F‐DCFPyL PET/CT fusion data in a patient with metastatic clear cell renal cell carcinoma. BJUI Compass. 2024; 5(6): 662–664. 10.1002/bco2.324
Çetinel B, Kalender G, Kırlı EA, Yenilmez A, Gülpınar Ö, Şimşir A, et al. Unilateral J‐cut division versus partial and subtotal removal techniques in female patients with mesh‐related urethral obstruction: multicentric comparative study. BJUI Compass. 2024; 5(6): 665–671. 10.1002/bco2.350
Juliebø‐Jones P, Gauhar V, Lim EJ, Traxer O, Madarriaga YQ, Castellani D, Fong KY, Bujons A, Ragoori D, Shrestha A, Vaddi CM, Bhatia TP, Sekerci CA, Tanidir Y, Teoh JY, Somani BK Outcomes and considerations for retrograde intrarenal surgery (RIRS) in the setting of multiple and large renal stones (>15 mm) in children: findings from multicentre and real‐world setting. BJUI Compass. 2024; 5(6): 672–677. 10.1002/bco2.357
Adesanya O, Rojanasarot S, McGovern AM, Burnett AL. Racial and socioeconomic disparities in surgical care for post‐prostate cancer treatment complications: a nationwide Medicare‐based analysis. BJUI Compass. 2024; 5(6): 678–689. 10.1002/bco2.342
Omidele OO, Connors C, Wainganker N, Badani K, Sfakianos J, Mehrazin R, Jayaratna I Prognostic factors and treatment impact on overall survival in patients with renal neuroendocrine tumour. BJUI Compass. 2024; 5(6): 690–698. 10.1002/bco2.341
Plage H, Furlano K, Neymeyer J, Weinberger S, Gerdes B, Hubatsch M, Ralla B, Franz A, Fendler A, de Martino M, Roßner F, Schallenberg S, Elezkurtaj S, Kluth M, Lennartz M, Blessin NC, Marx AH, Samtleben H, Fisch M, Rink M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Minner S, Simon R, Sauter G, Weischenfeldt J, Klatte T, Schlomm T, Horst D, Zecha H, Slojewski M CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course. BJUI Compass. 2024; 5(6): 699–706. 10.1002/bco2.354
Sutherland R, Gross CP, Ma X, Jeong F, Seibert TM, Cooperberg MR, Catalona WJ, Ellis SD, Loeb S, Schulman‐Green D, Leapman MS ‘It just makes sense to me’: a qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass. 2024; 5(6): 707–715. 10.1002/bco2.351
Shahait M, Ibrahim S, Baqain L, Abdul‐Sater Z. Bibliometric analysis of focal therapy in prostate cancer research. BJUI Compass. 2024; 5(6): 716–723. 10.1002/bco2.353
VOLUME 5, ISSUE 7
Bhojani N, Chew BH, Bhattacharyya S, Krambeck AE, Ghani KR, Miller LE. Effect of preoperative alpha‐blockers on ureteroscopy outcomes: a meta‐analysis of randomized trials. BJUI Compass. 2024; 5(7): 727–734. 10.1002/bco2.358
Bhatia A, Porto JG, Titus RS, Ila V, Shah K, Malpani A, Lopategui DM, Marcovich R, Herrmann TRW, Shah HN A systematic review and network meta‐analysis comparing Rezūm with transurethral needle ablation and microwave thermotherapy for the management of enlarged prostate. BJUI Compass. 2024; 5(7): 735–749. 10.1002/bco2.361
Warren H, Fanshawe JB, Mok V, Iyer P, Chan VW‐S, Hesketh R, et al. Imaging modalities for characterizing T1 renal tumours: a systematic review and meta‐analysis of diagnostic accuracy. BJUI Compass. 2024; 5(7): 750–764. 10.1002/bco2.355
Klempfner H, Anderson P. Comparison of staging MRI to re‐resection for localized bladder cancer: narrative review. BJUI Compass 2024; 5(7): 765–775. 10.1002/bco2.365
Gabb H, Gnanapragasam VJ. Value of a confirmatory re‐biopsy as part of a modern risk stratified cancer surveillance programme for early prostate cancer. BJUI Compass. 2024; 5(7): 776–778. 10.1002/bco2.406
Gelikman DG, Harmon SA, Kenigsberg AP, Law YM, Yilmaz EC, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B Evaluating a deep learning AI algorithm for detecting residual prostate cancer on MRI after focal therapy. BJUI Compass. 2024; 5(7): 779–781. 10.1002/bco2.373
Torenvlied HJ, Trip E, Olthuis W, Segerink LI, Pelger RCM, Beck JJH. ‘Feeling hot’: exploring the feasibility of nocturnal erection detection through penile temperature measurements. BJUI Compass. 2024; 5(7): 782–788. 10.1002/bco2.372
Thakur M, Tomar VS, Dale E, Gomella LG, Solomides C, Kolesnikov O, Keith SW, Navarro HT, Dahlgren O, Chaga M, Trabulsi EJ Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia. BJUI Compass. 2024; 5(7): 789–794. 10.1002/bco2.362
Mbouche LO, Mbassi AA, Mekeme JBM, Bob DN, Ndjock JL, Tamufor EN, Tambo FM Characteristics and management of post‐circumcision Urethrocutaneous fistula: a retrospective study in surgical units in Cameroon. BJUI Compass. 2024; 5(7): 795–804. 10.1002/bco2.391
Zhou Y, Lyratzopoulos G, Rajan P, Walter FM, Wu J. Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis. BJUI Compass. 2024; 5(7): 805–812. 10.1002/bco2.360
Brandt SB, Ibsen L, Lam GW, Bøttcher M, Kingo PS, Jensen JB. Ureteroenteric strictures after cystectomy: side‐specific risk factors and radiological assessment. BJUI Compass. 2024; 5(7): 813–822. 10.1002/bco2.364
Sasaki T, Kobayashi I, Uchida K, Higashi S, Masui S, Nishikawa K, Tsuzuki T, Watanabe M, Sassa N, Inoue T Cribriform pattern 4/intraductal carcinoma of the prostate and persistent prostate‐specific antigen after radical prostatectomy. BJUI Compass. 2024; 5(7): 823–831. 10.1002/bco2.367
VOLUME 5, ISSUE 8
Carey C, Gurumurthy G, Napier‐Hemy R, Zelhof B. A review of the current treatment methods for retroperitoneal fibrosis with obstructive uropathy. BJUI Compass. 2024; 5(8): 835–845. 10.1002/bco2.371
Christensen VS, Skow M, Flottorp SA, Strømme H, Mdala I, Vallersnes OM. Immediate or delayed trial without catheter in acute urinary retention in males: a systematic review. BJUI Compass. 2024; 5(8): 846–861. 10.1002/bco2.369
Lim S, Lim KY‐Y, Qu L, Ranasinha S, Dat A, Brown M, et al. Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: a meta‐analysis. BJUI Compass 2024; 5(8): 862–874. 10.1002/bco2.366
Françot M, Lefevre C, Reiss B, Lefort M, Karam G, Rigaud J, le Normand L, Ruffion A, Perrouin‐Verbe B, Perrouin‐Verbe MA Indications and added value of videourodynamics in men with spinal cord injury. BJUI Compass. 2024; 5(8): 875–883. 10.1002/bco2.370
Parkin CJ, Jyoti R, Chin P. Multiparametric‐magnetic resonance imaging (mp‐MRI) of the prostate and Urolift: identifying artefact size, location and clinical implications. BJUI Compass. 2024; 5(8): 884–889. 10.1002/bco2.392
Chen X, Zhao K, Wang H, Zhang C, Du L, Wang W, et al. Trans‐rectovesical pouch urethral‐sparing robotic‐assisted simple prostatectomy: a case series. BJUI Compass. 2024; 5(8): 890–896. 10.1002/bco2.389
Hillers AH, Bach SW, Saito A, Azawi N. Muscle matters: skeletal muscle index and body mass index impact on complications and survival in renal cancer. BJUI Compass. 2024; 5(8): 897–904. 10.1002/bco2.405
Bencina G, Billeskov R, Bak R, Al‐Sabbagh A, Pedersen JH, Lunetcas M, et al. Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort. BJUI Compass. 2024; 5(8): 905–912. 10.1002/bco2.375
Ajami T, Han S, Blachman‐Braun R, Hougen HY, Avda Y, Gonzalgo ML, Nahar B, Punnen S, Parekh DJ, Reis IM, Ritch CR Optimal Management for primary high grade ta bladder cancer: role of re‐staging TURBT and Intravesical adjuvant therapy. BJUI Compass. 2024; 5(8): 913–919. 10.1002/bco2.363
Hattori Y, Nagoshi A, Fujiwara T, Kambe T, Mine Y, Hagimoto H, Abe Y, Yamashita D, Tsutsumi N, Shibasaki N, Yamasaki T, Kawakita M Safety of urethral preservation using urethral frozen section analysis in radical cystectomy. BJUI Compass. 2024; 5(8): 920–924. 10.1002/bco2.377
VOLUME 5, ISSUE 9
Qin S, Chislett B, Ischia J, Ranasinghe W, Silva Dde, Coles‐Black J, et al. ChatGPT and generative AI in urology and surgery—a narrative review. BJUI Compass. 2024; 5(9): 927–935. 10.1002/bco2.390
Dawson J, Green K, Lazarowicz H, Cornford P, Probert C. Analysis of urinary volatile organic compounds for prostate cancer diagnosis: a systematic review. BJUI Compass. 2024; 5(9): 936–947. 10.1002/bco2.423
Anbarasan T, Raslan M, Ghosh K, Macklin P, Mercader C, Leslie T, Hamdy FC, Colling R, Browning L, Roberts I, Verrill C, Bryant RJ, Lopez F, Lamb AD Prostate cancer detection after atypical small acinar proliferation (ASAP): a 10‐year single‐Centre cohort. BJUI Compass. 2024; 5(9): 948–950. 10.1002/bco2.407
Trip EJ, Torenvlied HJ, Elzevier HW, Pelger RCM, Beck JJH. Shedding light on night‐time erections: determining the feasibility of nocturnal erection detection with penile transdermal light reflection of haemoglobin. BJUI Compass. 2024; 5(9): 951–958. 10.1002/bco2.410
Kapriniotis K, Loufopoulos I, Nobrega R, Noah A, Gresty H, Greenwell T, Ockrim J Day‐case artificial urinary sphincter for post‐prostatectomy incontinence: a comparative pilot study. BJUI Compass. 2024; 5(9): 959–964. 10.1002/bco2.412
Chislett B, Perera S, Perera M, Bolton D, Ischia J, Lawrentschuk N. Bleeding us dry: the financial impact of full blood examinations in the immediate postoperative period. BJUI Compass. 2024; 5(9): 965–968. 10.1002/bco2.368
Merriel SWD, Buttle P, Price SJ, Burns‐Cox N, Walter FM, Hamilton W, Spencer AE Early economic evaluation of magnetic resonance imaging for prostate cancer detection in primary care. BJUI Compass. 2024; 5(9): 969–978. 10.1002/bco2.409
Li EV, Kumar SK, Aguiar JA, Siddiqui MR, Neill C, Sun Z, Schaeffer EM, Jawahar A, Ross AE, Patel HD Utility of dynamic contrast enhancement for clinically significant prostate cancer detection. BJUI Compass. 2024; 5(9): 979–987. 10.1002/bco2.415
Dunsmore J, Duncan E, MacLennan SJ, N'Dow J, Cornford P, Esperto F, Pavan N, Ribal MJ, Roobol MJ, Skolarus TA, MacLennan S Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer. BJUI Compass. 2024; 5(9): 988–998. 10.1002/bco2.411
Roldan FL, Falagario UG, Olsson M, Salas RS, Aly M, Egevad L, Lantz A, Grönberg H, Akre O, Hosseini A, Wiklund NP Long‐term oncological outcomes after multimodal treatment for locally advanced prostate cancer. BJUI Compass. 2024; 5(9): 999–1006. 10.1002/bco2.414
VOLUME 5, ISSUE 10
Tzelves L, Geraghty R, Juliebø‐Jones P, Yuan Y, Kapriniotis K, Castellani D, Gauhar V, Skolarikos A, Somani B Suction use in ureterorenoscopy: a systematic review and meta‐analysis of comparative studies. BJUI Compass. 2024; 5(10): 1009–1026. 10.1002/bco2.408
Shanker MD, Yu ZH, Yang J, Matin S, Campbell MT, Msaouel P, Tannir N, Prajapati S, Ding Y, Lee B, Sobremonte A, Tang C MR‐Linac‐guided stereotactic radiotherapy for CT‐indiscernible intravascular renal cell carcinoma tumours. BJUI Compass. 2024; 5(10): 1027–1029. 10.1002/bco2.428
Xue J‐D, Zhang P, Xu Y‐M, Sa Y‐L, Shu H‐Q, Wang L, Xie H, Li C, Zhang W, Feng C, Wu DL Clinical application values of a novel synthetic training simulator for bulbar urethral anastomosis. BJUI Compass. 2024; 5(10): 1030–1037. 10.1002/bco2.426
Pikul M, Pfister D, Rieger C, Bach C, Voylenko O, Stakhovskyi O, Semko S, Vitruk I, Kononenko O, Stakhovsky E, Heidenreich A Ureter‐ileum‐interposition: combined experience from two high‐volume centres. BJUI Compass. 2024; 5(10): 1038–1047. 10.1002/bco2.434
Sandberg M, Cohen A, Escott M, Marie‐Costa C, Temple D, Rodriguez R, Gordon A, Rong A, Andres‐Robusto B, Roebuck EH, Ye E, Underwood G, Choudhary A, Whitman W, Webb CJ, Stratta RJ, Wood K, Assimos D, Mirzazadeh M Renal transplant nephrolithiasis: presentation, management and follow‐up with control comparisons. BJUI Compass. 2024; 5(10): 1048–1055. 10.1002/bco2.436
Saitta C, Paciotti M, Lughezzani G, Garofano G, Meagher MF, Yuen KL, Fasulo V, Contieri R, Avolio PP, Piccolini A, Arena P, Mantovani M, Beatrici E, Calatroni M, Reggiani F, Hurle RF, Lazzeri M, Saita A, Casale P, Derweesh IH, Buffi NM Impact of Mayo adhesive probability score and BMI on renal functional decline after robotic assisted partial nephrectomy. BJUI Compass. 2024; 5(10): 1056–1063. 10.1002/bco2.417
Sato K, Sazuka T, Arai T, Sato H, Kanesaka M, Ando K, Saito S, Pae S, Yamada Y, Imamura Y, Sakamoto S, Ichikawa T Machine learning analysis for detecting late recurrence and loss to follow‐up after renal cell carcinoma surgery. BJUI Compass. 2024; 5(10): 1064–1070. 10.1002/bco2.425
Kiyota S, Yoshida T, Nakamoto T, Jino E, Mishima T, Kinoshita H. Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: a retrospective pilot study. BJUI Compass. 2024; 5(10): 1071–1074. 10.1002/bco2.419
Kuppanda P, Hermans L, Uren A, Cotterill N, Rowe E, Narahari K, Dickinson A, Rigby J, Aning J, C‐PAT Study Group (#) and the BAUS Section of Oncology , Featherstone J, Okpii E National audit of patient reported experience of radical cystectomy for bladder cancer pathways. BJUI Compass. 2024; 5(10): 1075–1082. 10.1002/bco2.422
Langley S, Goad J, Bell S, Foster L, Hodges C, Laniado M, Pietrasik M., Rooke A., Knight M., Bosonnet E., Bott S. Targeted prostate health checks, a novel system to identify men with prostate cancer—a pilot study. BJUI Compass. 2024; 5(10): 1083–1089. 10.1002/bco2.416
Loeb S, Robbins R, Sanchez‐Nolasco T, Byrne N, Ruan A, Rivera A, Gupta N, Kenfield SA, Chan JM, van Blarigan E, Carter P, Jean‐Louis G, Orstad SL Sleep and health improvement programme (SHIP) for patients with prostate cancer and caregivers. BJUI Compass. 2024; 5(10): 1090–1099. 10.1002/bco2.435
Priester A, Mota SM, Grunden KP, Shubert J, Richardson S, Sisk A, Felker ER, Sayre J, Marks LS, Natarajan S, Brisbane WG Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm. BJUI Compass. 2024; 5(10): 1100–1111. 10.1002/bco2.421
VOLUME 5, ISSUE 11
Alexander CE, Nathan A, Light A, Gao C, Chan V, Khadhouri S, Gallagher K, Byrnes KG, Walters M, Hughes T, Perry R, Okoth K, Magill L, Pinkney T, John JB, McGrath J, Colquhoun A, Zhang Y, Blackmur J, Etchill E, Tang S, García Escudero D, Stewart G, Kasivisvanathan V, COVIDSurg Collaborative . Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐month follow‐up data from the international, prospective COVIDSurg cancer study. BJUI Compass. 2024; 5(11): 1158–1165. 10.1002/bco2.432
Ashraf W, Hamid A, Malik SA, Khawaja R, Para SA, Wani MS, Mehdi S Integrated enhanced recovery after surgery protocol in radical cystectomy for bladder tumour—a retroprospective study. BJUI Compass. 2024; 5(11): 1183–1194. 10.1002/bco2.438
Avudaiappan AP, Prabhakar P, Siretskiy R, Renshaw A, Eldefrawy A, Manoharan M. Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer. BJUI Compass. 2024; 5(11): 1204–1208. 10.1002/bco2.446
Berjaoui MB, Nguyen D‐D, Almousa S, Daher K, Barber N, Bidair M, Gilling P, Anderson P, Zorn KC, Badlani G, Humphreys M, Kaplan S, Kaufman RP Jr, Elterman D, Desai M, Roehrborn C, Bhojani N WATER versus WATER II 5‐year update: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates. BJUI Compass. 2024; 5(11): 1137–1147. 10.1002/bco2.430
Bhatt NR, Ippoliti S, Nambiar A, Ilie C, Doherty R, Smith L. Outcome of post‐prostatectomy stress urinary incontinence surgery in men with preoperative idiopathic detrusor overactivity. BJUI Compass. 2024; 5(11): 1115–1124. 10.1002/bco2.442
Deol ES, Nabavizadeh R, Lavoie RR, Dumbrava MG, Horjeti E, Thapa P, Cheville JC, Frank I, Lucien F Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer. BJUI Compass. 2024; 5(11): 1166–1172. 10.1002/bco2.418
Furlano K, Plage H, Hofbauer S, Weinberger S, Ralla B, Fendler A, Roßner F, Schallenberg S, Elezkurtaj S, Kluth M, Lennartz M, Blessin NC, Marx AH, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Koch S, Adamini N, Minner S, Simon R, Sauter G, Weischenfeldt J, Klatte T, Schlomm T, Horst D, Zecha H Reduced p63 expression is linked to unfavourable prognosis in muscle‐invasive urothelial carcinoma of the bladder. BJUI Compass. 2024; 5(11): 1195–1203. 10.1002/bco2.431
Hegarty PK, Kalantar M, Hegarty PA, Zafirakis H, Monahan JE. Bilateral orchidopexy for intermittent testicular torsion. BJUI Compass. 2024; 5(11): 1131–1136. 10.1002/bco2.439
Hughes S, Nair R, Radia B, Mavuduru RS, Dasgupta P, Ghose A. Indian consensus statements on the management of small renal masses, non‐muscle invasive bladder cancer and high‐risk/locally advanced prostate cancer. BJUI Compass. 2024; 5(11): 1148–1157. 10.1002/bco2.440
Mannion L, Watson V, Mullassery V, Nair R, Charlton T, Northover M, Enting D, van Hemelrijck M, Khan MS, Thurairaja R, Amery S, Chatterton K, Smith K, Hughes S Treatment preferences of patients with muscle invasive bladder cancer: a discrete choice experiment. BJUI Compass. 2024; 5(11): 1173–1182. 10.1002/bco2.443
Seikkula H, Hyysalo J, Högerman M, Boström PJ, Ettala O. The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy. BJUI Compass. 2024; 5(11): 1220–1227. 10.1002/bco2.413
Wei G, Sewell JAS, Bartolo C, Pearce A, Harris O, Grills R. Uropathogen antibiogram regional variations—are Australian antimicrobial guidelines appropriate? BJUI Compass. 2024; 5(11): 1125–1130. 10.1002/bco2.429
Yang Z‐H, Wang Y‐Z, Liu T, Zheng H, Wang X‐H. Dorsal venous complex ligation‐free and parietal endopelvic fascia preserving in laparoscopic radical prostatectomy: a prospective study of single Centre. BJUI Compass. 2024; 5(11): 1215–1219. 10.1002/bco2.437
Zahalka AH, Fram E, Garden E, Howard L, Wiggins E, Babar M, Annam J, Reagan A, Eilender B, de Hoedt A, Freedland SJ, Tewari A, Watts KL Association between beta‐blocker atenolol use and prostate cancer upgrading in active surveillance. BJUI Compass. 2024; 5(11): 1209–1214. 10.1002/bco2.441
We apologize for these errors.